IT Press Releases: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on IT Press Releases.

Press releases published on April 17, 2026

Apr. 17, 2026

TTEC Schedules First Quarter 2026 Earnings Release and Webcast of Investor Conference Call

Indeterminate GlobeNewswire

Apr. 17, 2026

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

Indeterminate GlobeNewswire

Apr. 17, 2026

Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting

Indeterminate GlobeNewswire

Apr. 17, 2026

4DMT Announces New Employment Inducement Grants

Indeterminate GlobeNewswire

Apr. 17, 2026

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Apr. 17, 2026

SEALSQ Announces Agenda of its 2026 Annual General Meeting of Shareholders

Indeterminate GlobeNewswire

Apr. 17, 2026

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting

Indeterminate GlobeNewswire

Apr. 17, 2026

Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026

Indeterminate GlobeNewswire

Apr. 17, 2026

Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Indeterminate GlobeNewswire

Apr. 17, 2026

Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types

Indeterminate GlobeNewswire

Apr. 17, 2026

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

Indeterminate GlobeNewswire

Apr. 17, 2026

Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting

Indeterminate GlobeNewswire

Apr. 17, 2026

Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting

Indeterminate GlobeNewswire

Apr. 17, 2026

Introspect Technology Adds New ATE-on-Bench Solution for LPDDR6, DDR6, and HBM Interfaces

Indeterminate GlobeNewswire

Apr. 17, 2026

Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026

Indeterminate GlobeNewswire

Apr. 17, 2026

Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial

Indeterminate GlobeNewswire

Apr. 17, 2026

Surgery Partners, Inc. Announces First Quarter 2026 Earnings Release Date and Conference Call Details

Indeterminate GlobeNewswire

Apr. 17, 2026

PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma

Indeterminate GlobeNewswire

Apr. 17, 2026

Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026

Indeterminate GlobeNewswire

Apr. 17, 2026

New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma

Indeterminate GlobeNewswire